ECSP044862A - Pirenzepine ophthalmic gel - Google Patents

Pirenzepine ophthalmic gel

Info

Publication number
ECSP044862A
ECSP044862A EC2004004862A ECSP044862A ECSP044862A EC SP044862 A ECSP044862 A EC SP044862A EC 2004004862 A EC2004004862 A EC 2004004862A EC SP044862 A ECSP044862 A EC SP044862A EC SP044862 A ECSP044862 A EC SP044862A
Authority
EC
Ecuador
Prior art keywords
ophthalmic gel
pirenzepine
pirenzepine ophthalmic
gel
pyrenzepine
Prior art date
Application number
EC2004004862A
Other languages
English (en)
Inventor
Harun Takruri
Original Assignee
Valley Forge Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Forge Pharmaceuticals filed Critical Valley Forge Pharmaceuticals
Publication of ECSP044862A publication Critical patent/ECSP044862A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Es un objeto primario de la presente invención proporcionar una formulación oftálmica acuosa, para tratar la miopía, ésta formulación comprende la pirenzepina en combinación con un portador de gel, aceptable farmacéuticamente
EC2004004862A 2001-05-25 2004-01-23 Pirenzepine ophthalmic gel ECSP044862A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29373101P 2001-05-25 2001-05-25

Publications (1)

Publication Number Publication Date
ECSP044862A true ECSP044862A (es) 2004-03-23

Family

ID=23130330

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004862A ECSP044862A (es) 2001-05-25 2004-01-23 Pirenzepine ophthalmic gel

Country Status (17)

Country Link
US (2) US20040137069A1 (es)
EP (1) EP1397132A4 (es)
JP (1) JP2004531569A (es)
KR (1) KR20040018380A (es)
CN (1) CN1509172A (es)
BR (1) BR0210013A (es)
CA (1) CA2447562A1 (es)
EC (1) ECSP044862A (es)
HU (1) HUP0304071A2 (es)
IL (1) IL158904A0 (es)
MX (1) MXPA03010655A (es)
NO (1) NO20035224D0 (es)
NZ (1) NZ529615A (es)
PL (1) PL366924A1 (es)
RU (1) RU2297831C2 (es)
WO (1) WO2002096418A1 (es)
ZA (1) ZA200309791B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008119A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
JP4963359B2 (ja) * 2005-01-12 2012-06-27 ロート製薬株式会社 眼局所適用製剤
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
US20100114309A1 (en) * 2006-12-26 2010-05-06 De Juan Jr Eugene Drug delivery implants for inhibition of optical defects
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
EP2207529B1 (en) 2007-09-07 2014-12-31 Mati Therapeutics Inc. Drug cores for sustained release of therapeutic agents
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
HUE070784T2 (hu) * 2010-10-25 2025-06-28 Univ Manitoba Terápiás készítmények diabéteszes szimmetrikus polineuropátia kezelésére
BR112013023458B1 (pt) * 2011-03-14 2020-04-07 Drug Delivery Solutions Ltd composição oftálmica, e, método para fabricar a composição oftálmica
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN105663137A (zh) * 2016-01-14 2016-06-15 王真 哌仑西平在制备治疗脓毒症疾病的药物中的应用
KR102580933B1 (ko) * 2016-05-25 2023-09-19 싱가포르 헬스 서비시즈 피티이 엘티디 아트로핀-함유 수성 조성물
CA3205816A1 (en) 2017-11-03 2019-05-09 Alcon Inc. Azabicyclo and diazepine derivatives for treating ocular disorders
EP3735209A4 (en) 2018-01-05 2021-09-08 University of Utah Research Foundation TREATMENT OF THE PROGRESSION OF MYOPOIA
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
US20220273671A1 (en) * 2019-03-26 2022-09-01 Winsantor, Inc. Topical formulations for treatment of peripheral neuropathies
KR20220018484A (ko) * 2019-06-10 2022-02-15 제니비젼 인크. 시력 장애를 치료하기 위한 방법 및 제형
AU2020311441B2 (en) * 2019-07-11 2025-12-04 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
KR102808906B1 (ko) * 2021-06-18 2025-05-19 대우제약 주식회사 고점도 점안제를 무균여과하는 방법
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法
WO2025171327A1 (en) * 2024-02-09 2025-08-14 Levation Pharma Ltd. Methods for producing dermatological gel compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
ES2136686T3 (es) * 1989-06-21 1999-12-01 Univ Pennsylvania Tratamiento y control de desarrollo ocular con agonistas colinergicos.
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
SU1827797A3 (ru) * 1991-04-30 1996-05-20 Н.Б. Леонидов Лекарственный препарат для анестезии глаз
US5461808A (en) * 1993-02-08 1995-10-31 Fritts; Robert W. Table top backlit display
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
RU2135129C1 (ru) * 1998-11-18 1999-08-27 Ларионов Евгений Викторович Глазные капли "корнеалон-плюс"
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia

Also Published As

Publication number Publication date
EP1397132A1 (en) 2004-03-17
JP2004531569A (ja) 2004-10-14
KR20040018380A (ko) 2004-03-03
WO2002096418A1 (en) 2002-12-05
MXPA03010655A (es) 2007-06-22
IL158904A0 (en) 2004-05-12
US20040137069A1 (en) 2004-07-15
NZ529615A (en) 2005-07-29
BR0210013A (pt) 2004-08-10
ZA200309791B (en) 2004-10-04
HUP0304071A2 (hu) 2004-04-28
US20060188576A1 (en) 2006-08-24
RU2003136735A (ru) 2005-03-27
CN1509172A (zh) 2004-06-30
EP1397132A4 (en) 2006-12-13
PL366924A1 (en) 2005-02-07
RU2297831C2 (ru) 2007-04-27
NO20035224D0 (no) 2003-11-24
CA2447562A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
CY1117417T1 (el) Νιτροοξυπαραγωγα προσταγλανδινης
HN1999000015A (es) Tratamiento para una disfuncion sexual femenina
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
AU3831301A (en) Method for treating ocular pain
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DE60331638D1 (de) Keratin-netzwerke enthaltende wundverbände für gewebedefekte
CY1106409T1 (el) Παραγωγα κινολινης
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
CR7198A (es) Tableta que contiene cetirizina y pseudoefedrina
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
ITMI20021860A1 (it) Impiego dei triptani come agenti antivirali.
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa